What's in Gao-jun Teng's pipeline?

Gao-jun Teng has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Gao-jun Teng's portfolio?

Top competitors by shared drug class: Amgen, Biocad, Cancer Trials Ireland, Celgene, Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/gao-jun-teng.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Gao-jun Teng — Portfolio Competitive Intelligence Brief

Gao-jun Teng pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Dicycloplatin (TP21)	Dicycloplatin (TP21)	phase 3	Platinum-based chemotherapy agent	DNA	Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Amgen · 1 shared drug class
Biocad · 1 shared drug class
Cancer Trials Ireland · 1 shared drug class
Celgene · 1 shared drug class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
Chinese Academy of Medical Sciences · 1 shared drug class
Federation Francophone de Cancerologie Digestive · 1 shared drug class
Akeso · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Gao-jun Teng:

Cite this brief

Drug Landscape (2026). Gao-jun Teng — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gao-jun-teng. Accessed 2026-05-16.